TY - JOUR
T1 - Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
AU - Shetty, Akshay
AU - Buch, Adam
AU - Saab, Sammy
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/5/15
Y1 - 2019/5/15
N2 - As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.
AB - As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.
KW - DAA, direct-acting antiviral
KW - Donor grafts
KW - Hepatitis C liver transplantation
KW - Hepatitis C-positive donor grafts
KW - Liver transplantation
UR - http://www.scopus.com/inward/record.url?scp=85058698491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058698491&partnerID=8YFLogxK
U2 - 10.1007/s10620-018-5404-x
DO - 10.1007/s10620-018-5404-x
M3 - Review article
C2 - 30560331
AN - SCOPUS:85058698491
SN - 0163-2116
VL - 64
SP - 1110
EP - 1118
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 5
ER -